We now partner with Financial Exchange Radio to produce a weekly segment with Seeking Alpha authors.
Joe McCann continues the series with his bullish pick: Aurinia Pharmaceuticals.
Aurinia recently reported Phase 2 data for VOS in dry eye. The drug's efficacy was better and statistically significant compared to Restasis.
As investors do more work on the potential of VOS dry eye and understand its potential, shares will rise in value without typical biotech binary risks.